ADC Therapeutics SA
ANTI-IL13R ALPHA2 ANTIBODIES
Last updated:
Abstract:
This disclosure relates to antibodies that specifically bind to the Interleukin-13 receptor subunit alpha-2 (IL13R.alpha.2) protein, and associated uses and methods for production.
Status:
Application
Type:
Utility
Filling date:
30 Jul 2021
Issue date:
3 Feb 2022